Ubs Group Ag Adicet Bio, Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 53,538 shares of ACET stock, worth $77,630. This represents 0.0% of its overall portfolio holdings.

Number of Shares

53,538

Previous 22,578 137.12%

Holding current value

$77,630

Previous $42,000 197.62%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$1.76 - $3.45 $54,489 - $106,812	30,960 Added 137.12%	53,538 $125,000
Q4 2023 Feb 09, 2024	BUY	$1.11 - $1.89 $20,247 - $34,475	18,241 Added 420.59%	22,578 $42,000
Q3 2023 Nov 09, 2023	BUY	$1.37 - $3.4 $5,904 - $14,654	4,310 Added 15962.96%	4,337 $5,000
Q2 2023 Aug 11, 2023	BUY	$2.13 - $7.13 $57 - $192	27 New	27 $0
Q4 2022 Feb 08, 2023	BUY	$7.72 - $21.27 $774,470 - $2.13 Million	100,320 Added 580.93%	117,589 $1.05 Million

Q3 2022 Nov 10, 2022	BUY	$13.43 - $18.74 $231,922 - $323,621	17,269 New	17,269 $246,000
Q2 2022 Aug 10, 2022	SELL	$10.26 - $20.81 $5,612 - $11,383	-547 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$11.53 - $19.97 $107,667 - $186,479	-9,338 Reduced 94.47%	547 $11,000
Q4 2021 Feb 14, 2022	BUY	$7.37 - $17.49 $71,732 - $170,230	9,733 Added 6403.29%	9,885 $173,000
Q3 2021 Nov 15, 2021	BUY	$6.29 - $9.93 $956 - $1,509	152 New	152 $1,000
Q2 2021 Aug 13, 2021	SELL	$9.19 - $15.93 $15,558 - $26,969	-1,693 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$12.12 - $17.17 $13,562 - $19,213	1,119 Added 194.95%	1,693 $22,000
Q4 2020 Feb 11, 2021	SELL	$10.36 - $14.77 $8,557 - $12,200	-826 Reduced 59.0%	574 $8,000
Q3 2020 Nov 12, 2020	BUY	$10.18 - $21.4 $14,252 - $29,959	1,400 New	1,400 $17,000

Others Institutions Holding ACET

# of Institutions

107

Shares Held

69.5M

Call Options Held

13.3K

Put Options Held

24.6K

View Full List

About Adicet Bio, Inc.

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $58M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

More about ACET

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account